{"DataElement":{"publicId":"2794409","version":"1","preferredName":"Graft Versus Host Disease Therapeutic Procedure Or Preventive Intervention Immunosuppressant Final Administered End Date","preferredDefinition":"An incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._Therapeutic, nutritional, environmental, social and or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease._Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of suppressor T-cell populations or by inhibiting the activation of helper cells. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of interleukins and other cytokines are emerging._The act of having given something (e.g., a medication or test)._The point or place at which something terminates in time, space, or extent._a particular day specified as the time something has, or will, happen.","longName":"GVHD_TP_IM_AD_DT","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2794404","version":"1","preferredName":"Graft Versus Host Disease Therapeutic Procedure Or Preventive Intervention Immunosuppressant Final Administered","preferredDefinition":"An incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._Therapeutic, nutritional, environmental, social and or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease._Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of suppressor T-cell populations or by inhibiting the activation of helper cells. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of interleukins and other cytokines are emerging._The act of having given something (e.g., a medication or test).","longName":"GVHD_TP_PI_IM_FI_AD","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2814110","version":"1","preferredName":"Graft Versus Host Disease Therapeutic Procedure Or Preventive Intervention Immunosuppressant","preferredDefinition":"An incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:Or; used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:An attempt to prevent disease.:Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of suppressor T-cell populations or by inhibiting the activation of helper cells. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of interleukins and other cytokines are emerging.","longName":"C3063:C49236:C37998:C15843:C57","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Graft Versus Host Disease","conceptCode":"C3063","definition":"A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Preventive Intervention","conceptCode":"C15843","definition":"Therapeutic, nutritional, environmental, social and/or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunosuppressant","conceptCode":"C574","definition":"Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of suppressor T-cell populations or by inhibiting the activation of helper cells. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of interleukins and other cytokines are emerging.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5DB5848F-BF65-DAFD-E040-BB89A643158A","latestVersionIndicator":"Yes","beginDate":"2008-12-10","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-12-10","modifiedBy":"ONEDATA","dateModified":"2008-12-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"59DA78EC-B775-6F22-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-10-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-22","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2928085","version":"1","preferredName":"End Date","preferredDefinition":"The point or place at which something terminates in time, space, or extent._a particular day specified as the time something has, or will, happen.","longName":"END_DT","context":"NHLBI","contextVersion":"1","type":"Non-enumerated","dataType":"DATE","minLength":null,"maxLength":"10","minValue":null,"maxValue":null,"decimalPlace":null,"format":"YYYY-MM-DD","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008561","version":"1","preferredName":"Occurrences","preferredDefinition":"dates, times, and durations.","longName":"OCURS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B53BD1AB-090B-398B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-01-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2459822","version":"1","preferredName":"End Date","preferredDefinition":"The point or place at which something terminates in time, space, or extent.:a particular day specified as the time something has, or will, happen.","longName":"C25496:C25164","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"End","conceptCode":"C25496","definition":"The point or place at which something terminates in time, space, or extent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Date","conceptCode":"C25164","definition":"The particular day, month and year an event has happened or will happen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F0AEBD7-98F9-60D5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-16","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-03-16","modifiedBy":"ONEDATA","dateModified":"2006-03-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"707E9927-EE45-2700-E040-BB89AD4347DD","latestVersionIndicator":"Yes","beginDate":"2009-08-06","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-08-06","modifiedBy":"NYCHM","dateModified":"2010-12-02","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"}]},{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964902","version":"1","longName":"2100r1: 100 Days Post-HSCT Data","context":"NHLBI"},{"publicId":"2964922","version":"1","longName":"2200r1: 6 Month to 2 Year Post-HSCT Data","context":"NHLBI"},{"publicId":"2964923","version":"1","longName":"2300r1: Greater Than 2 Years Post-HSCT Data","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"cgvhd_trt_end_dte","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedSubstanceAdministration:dateRange","type":"HCT_BRIDG","context":"NHLBI"},{"name":"CCR","type":"USED_BY","context":"CCR"}],"ReferenceDocuments":[{"name":"What was the end date the imm","type":"Preferred Question Text","description":"What was the end date the immunosuppressive agents were administered to treat or prevent GVHD?","url":null,"context":"NHLBI"},{"name":"Date final treatment administered:","type":"Alternate Question Text","description":"Date final treatment administered:","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2794409","type":"BRIDG Mapping Path","description":"PerformedSubstanceAdministration.dateRange(IVL<TS.DATETIME>).high WHERE PerformedSubstanceAdministration > StudyAgent > Product.typeCode = \"Immunosuppressant\" AND PerformedSubstanceAdministration > DefinedSubstanceAdministration.reasonCode = \"prevent GVHD\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"59D993BE-0410-74E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-10-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-22","modifiedBy":"ALEYR","dateModified":"2019-04-07","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}